Search This Blog

Tuesday, February 7, 2017

Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study

Landmark Repatha Cardiovascular Outcomes Study Meets Primary and Key Secondary Endpoint
Detailed Results to be Presented at ACC 66th Annual Scientific Session


Amgen - Investors - RSS Content
Posted by at
Labels:

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)